Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies

This article was originally published in The Pink Sheet Daily

Executive Summary

An FDA alert about a cluster of Streptococcus endophthalmitis infections in Florida suggests concerns about aseptic conditions in pharmacies that repackage Avastin for off-label intravitreal use.
Advertisement

Related Content

Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4
NICE’s Off-Label Drug Guide Doesn’t Imply Support – Even For Pfizer
FDA’s Compounding Oversight: What Price Safety?
New U.K. NHS Bodies Authorize Avastin Use In AMD As Lucentis Pricing Pressures Continue
Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
Genentech Clarifies Avastin Off-Label Policy; Wholesale Distributors Key
Genentech Clarifies Avastin Off-Label Policy; Wholesale Distributors Key

Topics

Advertisement
UsernamePublicRestriction

Register

PS072716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel